Your NEJM Group Today: End-of-Life Decisions in Netherlands / Oxytocin & Autism / California EM Opportunities — Physician’s First Watch

Medical News |
August 7, 2017

Your NEJM Group Today: End-of-Life Decisions in Netherlands / Oxytocin & Autism / California EM Opportunities

By the Editors

Check out our latest selections from NEJM Group:

NEJM Clinical Practice Center: Correspondence: Data from physicians in the Netherlands show that the percentage of patients in whom an end-of-life decision preceded death increased from 39% in 1990 to 58% in 2015. During this time, the euthanasia rate increased from 1.7% to 4.5%. Continuous deep sedation was provided in 18% of all deaths in 2015.

NEJM Journal Watch Psychiatry : Among children with autism spectrum disorder, a nasal oxytocin spray improved social capacity, with the strongest effects in children with the lowest plasma oxytocin levels at baseline.

NEJM CareerCenter: Loma Linda University Faculty Medical Group in southern California is seeking full-time emergency medicine physicians to join its growing EM department.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.